clinical trials

First Opinion By Bobby Clark and Ronnie Tepp

Community engagement is key to clinical trial recruitment and diversity

First Opinion By Rebecca Li

Move clinical trial data sharing from an option to an imperative

First Opinion By Jen Goldsack

Synthetic control arms can save time and money in clinical trials

First Opinion By Louise Aronson

A new NIH rule won’t be enough to make clinical research more inclusive

First Opinion By Jeremy Farrar

It isn’t crazy to conduct an Ebola clinical trial in a war zone — it’s necessary

Pharmalot By Ed Silverman

Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker

First Opinion By Julia G. Brody

All study participants have a right to know their own results. My lab has been doing that for years

First Opinion By Jake LaPorte

Digital technologies hold the key to streamlining and improving clinical trials

Lessons Learned By Megha Satyanarayana

Lessons Learned: This is how you take a public health degree to a startup and back to academia

Pharmalot By Ed Silverman

Millions in fines are adding up as clinical trial information goes unreported

Adam's Take By Adam Feuerstein

Marinus Pharma finds the biotech imitation game can only last so long

Biotech By Adam Feuerstein

Dermira discontinues development of acne drug after two late-stage trials fail

First Opinion By Howard M. Fillit

FDA’s updated standards remove an unnecessary barrier to testing Alzheimer’s drugs

In the Lab By Andrew Joseph

How well can you predict the outcome of clinical trials? Not as well as you may think

Health By Marisa Taylor — Kaiser Health News

Unregulated herpes experiments expose ‘black hole’ of accountability

Biotech By Adam Feuerstein

Nabriva novel antibiotic meets goals in late-stage bacterial pneumonia study

Business By Adam Feuerstein

Stakes are high as Alnylam awaits results from novel rare disease therapy

Business By Adam Feuerstein

5 things to know about Sage’s must-win drug trials in postpartum depression

Pharma By Adam Feuerstein

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

Biotech By Adam Feuerstein

7 things to know about Sage Therapeutics’ pivotal trial of a drug for severe epilepsy

Biotech By Adam Feuerstein

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

First Opinion By Lynn O'Connor Vos

How do we solve the crisis in cancer communication?

Health By Rebecca Robbins

Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’

Gut Check By Sharon Begley

Do cancer clinical trials exaggerate the real-world benefits of drugs?

Pharmalot By Ed Silverman

How much longer will Gilead wait before buying its way out of the doldrums?